The STAREE-Mind imaging sub-study will examine the effect of statin treatment over a 4-year period, compared with placebo, on markers of brain health.
STAREE-Mind imaging is a sub-study nested in the Statins in Reducing Events in the Elderly (STAREE) double blind randomised placebo-controlled trial. STAREE is investigating whether statins can prolong good health and maintain independence amongst older people and is enrolling. STAREE-Mind imaging aims to recruit a sub-group of 340 participants, and will involve an additional suite of brain imaging in these participants, at recruitment (before medication is commenced) and at 4 years follow-up. It will provide crucial information about the clinical effects of statins on brain health in older individuals.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
341
40 mg atorvastatin (2 x 20 mg atorvastatin daily), taken orally
2 x 20mg placebo (daily), taken orally. Identical appearance to study drug
Herston Imaging Research Facility (HIRF)
Herston, Queensland, Australia
Monash Biomedical Imaging (MBI)
Clayton, Victoria, Australia
Free water
Multi-compartment free water quantitation from brain diffusion-weighted MRI
Time frame: Change from baseline to four years
White matter hyperintensity volume
From brain FLAIR MRI
Time frame: Change from baseline to four years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.